PMADS

Id:	acc3363
Group:	2sens
Protein:	beta-catenin
Gene Symbol:	CTNNB1
Protein Id:	P35222
Protein Name:	CTNB1_HUMAN
PTM:	phosphorylation
Site:	Tyr489
Site Sequence:	MAQNAVRLHYGLPVVVKLLHP
Disease Category:	Respiratory system diseases
Disease:	Bronchopulmonary Dysplasia
Disease Subtype:
Disease Cellline:
Disease Info:
Drug:	dasatinib
Drug Info:	Dasatinib is a medication used in the treatment of certain types of leukemia. It functions as a tyrosine - kinase inhibitor to block abnormal protein signaling in cancer cells.
Effect:	modulate
Effect Info:	Inhibiting the tyrosine kinase activity in organoids exposed to hypoxia - hyperoxia with dasatinib can prevent both the nuclear localization of p - β - cateninY489 and the expression of α - SMA.
Note:
Score:	4.0
Pubmed(PMID):	27941077
Sentence Index:	27941077_4-5
Sentence:	"When Wnt signaling is active, phosphorylation of beta-catenin by tyrosine kinases at activating sites, specifically at tyrosine 489 (Y489), correlates with nuclear localization of beta-catenin. We examined fetal lung tissue, lung tissue from term newborns, and lung tissue from infants who died with BPD; we found nuclear beta-catenin phosphorylation at Y489 in epithelial and mesenchymal cells in fetal tissue and BPD tissue, but not in the lungs of term infants."

Sequence & Structure:

MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
CTNNB1	PRI-724	CBP/beta catenin inhibitor	2	Withdrawn	colorectal adenocarcinoma	ClinicalTrials
CTNNB1	PRI-724	CBP/beta catenin inhibitor	2	Recruiting	cirrhosis of liver	ClinicalTrials
CTNNB1	PRI-724	CBP/beta catenin inhibitor	1	Completed	acute myeloid leukemia	ClinicalTrials
CTNNB1	PRI-724	CBP/beta catenin inhibitor	1	Completed	chronic myelogenous leukemia	ClinicalTrials
CTNNB1	PRI-724	CBP/beta catenin inhibitor	1	Terminated	neoplasm	ClinicalTrials
CTNNB1	PRI-724	CBP/beta catenin inhibitor	1	Completed	pancreatic carcinoma	ClinicalTrials
CTNNB1	PRI-724	CBP/beta catenin inhibitor	1	Completed	pancreatic adenocarcinoma	ClinicalTrials
CTNNB1	PRI-724	CBP/beta catenin inhibitor	1	Completed	Malignant Pancreatic Neoplasm	ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CTNNB1-Ser179
Cancer	Intensity
BRCA	-0.962
COAD	0.455
HGSC	1.973
ccRCC	-1.319
GBM	-0.972
HNSC	0.229
LUAD
LUSC
non_ccRCC	-0.072
PDAC	0.409
UCEC	0.257

CTNNB1-Ser191
Cancer	Intensity
BRCA	-1.014
COAD	-0.344
HGSC	0.922
ccRCC	-0.101
GBM	0.311
HNSC	0.693
LUAD	0.681
LUSC	0.136
non_ccRCC	1.119
PDAC	-2.383
UCEC	-0.021

CTNNB1-Ser222
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.549
HNSC
LUAD	-0.77
LUSC	1.445
non_ccRCC
PDAC
UCEC	-0.126

CTNNB1-Ser33
Cancer	Intensity
BRCA
COAD
HGSC	-1.746
ccRCC	0.213
GBM	1.104
HNSC	-0.324
LUAD	-0.011
LUSC
non_ccRCC
PDAC
UCEC	0.764

CTNNB1-Ser37
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.655
GBM	1.477
HNSC	-0.252
LUAD	-0.57
LUSC
non_ccRCC
PDAC
UCEC

CTNNB1-Ser45
Cancer	Intensity
BRCA
COAD	-0.184
HGSC	-1.332
ccRCC
GBM	0.613
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.904

CTNNB1-Ser552
Cancer	Intensity
BRCA	-1.793
COAD	-0.07
HGSC	0.724
ccRCC	1.879
GBM	-0.666
HNSC	0.383
LUAD	0.034
LUSC
non_ccRCC
PDAC	-0.172
UCEC	-0.318

CTNNB1-Ser675
Cancer	Intensity
BRCA	-0.341
COAD	-0.152
HGSC	2.444
ccRCC	-0.185
GBM	0.26
HNSC	0.094
LUAD	-0.329
LUSC	0.129
non_ccRCC	-0.617
PDAC	-1.752
UCEC	0.448

CTNNB1-Thr217
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	0.319
HNSC	0.802
LUAD	-1.121
LUSC
non_ccRCC
PDAC
UCEC

CTNNB1-Thr40
Cancer	Intensity
BRCA
COAD
HGSC	-0.707
ccRCC
GBM	0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

CTNNB1-Thr41
Cancer	Intensity
BRCA
COAD
HGSC	0.385
ccRCC
GBM	0.75
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-1.135

CTNNB1-Thr551
Cancer	Intensity
BRCA
COAD	0.362
HGSC	-1.588
ccRCC
GBM
HNSC	0.735
LUAD	0.046
LUSC	1.147
non_ccRCC
PDAC
UCEC	-0.701

CTNNB1-Thr556
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

CTNNB1-Tyr30
Cancer	Intensity
BRCA
COAD
HGSC	0.707
ccRCC
GBM
HNSC
LUAD	-0.707
LUSC
non_ccRCC
PDAC
UCEC

CTNNB1-Tyr716
Cancer	Intensity
BRCA
COAD	-0.807
HGSC	1.119
ccRCC
GBM	-0.312
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
-	-	A	Prostate cancer	Ubiquitination	30532005
S	45	A	Wilms tumor	Phosphorylation	12239584
S	33	A	Colorectal cancer	Phosphorylation	34240584
-	-	D	Cancer	Ubiquitination	30714168
S	45	D	Non-small cell lung cancer	Phosphorylation	35277183
S	552	D	Hepatocellular carcinoma	Phosphorylation	37573318
T	41	D	Retinoblastoma	Phosphorylation	35968358
K	49	D	Colorectal cancer	Acetylation	32355204
T	41	D	Head and neck squamous cell carcinoma	Phosphorylation	21281788
T	120	D	Prostate cancer/carcinoma/adenocarcinoma	Phosphorylation	22511927
S	552	D	Lung cancer	Phosphorylation	30918250
S	45	D	Head and neck squamous cell carcinoma	Phosphorylation	21281788
S	45	D	Colon cancer	Phosphorylation	32041324
S	45	D	Esophageal carcinoma	Phosphorylation	31933784
S	33	D	Retinoblastoma	Phosphorylation	35968358
-	-	D	Colorectal cancer	Ubiquitination	29789528
-	-	D	Gastric cancer	Ubiquitination	31747856
S	33	D	Primary hyperparathyroidism	Phosphorylation	22576020
S	37	D	Retinoblastoma	Phosphorylation	35968358
S	37	D	Primary hyperparathyroidism	Phosphorylation	22576020
S	45	N	Cutaneous melanoma	Phosphorylation	11351304
S	45	N	Colorectal cancer	Phosphorylation	11955436
T	41	N	Colorectal cancer	Phosphorylation	11955436
S	37	N	Colorectal cancer	Phosphorylation	11955436
S	33	N	Colorectal cancer	Phosphorylation	11955436
S	45	N	Wilms tumor	Phosphorylation	12239584
S	45	N	Nephroblastoma	Phosphorylation	12239584
Y	654	P	Intestinal cancer	Phosphorylation	21307168
-	-	P	Prostate cancer/carcinoma/adenocarcinoma	Phosphorylation	24088787
-	-	P	Colorectal cancer	Ubiquitination	31527801
-	-	P	Epithelial ovarian cancer	Ubiquitination	37186433
-	-	P	Gastric cancer	Ubiquitination	33159601
T	40	P	Colorectal cancer	Phosphorylation	34240584
K	394	U	Breast adenocarcinoma	Ubiquitination	22705350
K	19	U	Colorectal cancer	Ubiquitination	29674637
-	-	U	Prostate cancer	Ubiquitination	35637955
-	-	U	Hepatocellular carcinoma	Ubiquitination	29189991
-	-	U	Renal cell carcinoma	Ubiquitination	31926310
-	-	U	Colorectal cancer	Ubiquitination	37424824
S	552	U	Cholangiocarcinoma	Phosphorylation	36928362
-	-	U	Lung cancer	Ubiquitination	37726816
-	-	U	Pancreatic cancer	Ubiquitination	34325342
-	-	U	Hepatocellular carcinoma	Ubiquitination	35568970
S	552	U	Glioblastoma	Phosphorylation	36435833
S	675	U	Glioblastoma	Phosphorylation	32102932
S	675	U	Intrahepatic cholangiocarcinoma	Phosphorylation	29415992
S	552	U	Colorectal cancer	Phosphorylation	35059735
S	33	U	Colorectal cancer	Phosphorylation	37369481
K	49	U	Non-small cell lung cancer	Acetylation	35277183
-	-	U	Colorectal cancer	Acetylation	29563608
K	49	U	Colorectal cancer	Acetylation	32355204
S	675	U	Lung cancer	Phosphorylation	36000549
S	33	U	Melanoma	Phosphorylation	17001009
S	37	U	Colorectal cancer	Phosphorylation	37369481
S	184	U	Hepatocellular carcinoma	Phosphorylation	36808719
S	552	U	Clear cell kidney cancer	Phosphorylation	34657130
S	552	U	Colitis	Phosphorylation	20580720
S	675	U	Hepatocellular carcinoma	Phosphorylation	36000549
S	311	U	Non-small cell lung cancer	Phosphorylation	36793862
T	41	U	Colorectal cancer	Phosphorylation	37369481
Y	333	U	Glioblastoma	Phosphorylation	22056988
-	-	U	Triple-negative breast cancer	Phosphorylation	33407765
-	-	U	Non-small cell lung cancer	Phosphorylation	35986102
-	-	U	Papillary thyroid carcinoma	Phosphorylation	35350839
S	552	U	Non-functioning pituitary tumours	Phosphorylation	36114575
S	552	U	Osteoarthritis	Phosphorylation	36439631
S	675	U	Cholangiocarcinoma	Phosphorylation	34799729
Y	654	U	Idiopathic pulmonary fibrosis	Phosphorylation	19104148
Y	654	U	Nasopharyngeal carcinoma	Phosphorylation	37496925

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb